RecruitingNon-small Cell Lung Cancer (NSCLC)
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Eligible age
18+ yrs
Accepts
All genders
Locations
19 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)
Sponsor: Bristol-Myers Squibb
You may qualify if…
- ✓ Participants must have a histologically- or cytologically-confirmed diagnoses of non-small cell lung cancer (NSCLC) with unresectable Stage III disease.
- ✓ Participants must have received at least 2 cycles of platinum-based concurrent chemoradiotherapy (a total dose of radiation of at least 54 Gy).
- ✓ Participants must have no progressive disease (PD) following treatment with concurrent chemoradiotherapy (CCRT).
- ✓ Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.
You may not qualify if…
- ✕ Participants with non-squamous histology must not have documented Epidermal Growth Factor Receptor (EGFR) and anaplastic lymphoma kinase (ALK) rearrangements.
- ✕ Participants must not have an active autoimmune disease.
- ✕ Participants must not have significant cardiovascular impairment such as uncontrolled hypertension (despite optimal medical treatment), congestive heart failure, active coronary disease (within 6 months prior to randomization), ventricular arrhythmias, major thrombotic or embolic events or major hemorrhagic events within 6 months prior to randomization, or significant risk of pulmonary hemorrhage.
- ✕ Participants must not have advanced/clinically significant lung disease (within 6 months prior to randomization) or history of interstitial lung disease (ILD) or pneumonitis requiring treatment with systemic steroids (≥ Grade 2), or current or suspected ILD or pneumonitis.
- ✕ Participants must not have any prior anticancer therapy (outside of CCRT) for locally advanced Stage III disease.
- ✕ Other protocol-defined Inclusion/Exclusion criteria apply.
Where it's recruiting
Source: ClinicalTrials.gov · NCT07361497 · last updated 2026-11-05